札幌医学雑誌　87（1 － 6）9 ～ 23（2018）　doi：10.15114/smj.87.9

総説

脳神経内科疾患研究の歩み

下濱　俊
札幌医科大学医学部神経内科学講座

Research activities on neurological disorders up to the present

Shun SHIMOHAMA
Department of Neurology, Sapporo Medical University School of Medicine

ABSTRACT

To offer the best quality of life for patients suffering from various kinds of neurological disorders, I have been conducting numerous matters of clinical and basic research. My main interests include neurobiology and treatment of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis. I also conduct research on demyelinating diseases and autoimmune disorders such as myasthenia gravis with our colleagues. We study the molecular mechanisms of AD, and are trying to develop a novel therapy for it. Accumulation of activated microglia in and around senile plaques has been demonstrated in autopsied brains from AD patients, and is believed to modulate amyloid-beta clearance, inflammation and oxidative stress. Findings from our recent research suggest that microglial activation changes with progression of AD expressing several marker molecules. To explore a novel therapy against PD, we evaluated the therapeutic effects of an alpha-7 nicotinic acetylcholine receptor agonist and human bone marrow-derived mesenchymal stem cells. Excitation–contraction (E–C) coupling of skeletal muscles has been a somewhat under-explored field in clinical neurophysiology. We have explored the impaired post-tetanic potentiation of muscle twitch and the effect of local cooling on E-C coupling in myasthenia gravis.

(Accepted November 13, 2018)

Key words: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, demyelinating diseases, myasthenia gravis

はじめに

札幌医科大学医学部神経内科学講座は，1992 年 4 月に附属病院診療科の神経内科として開設され，2008 年 4 月に診療科から医学部神経内科学講座へと昇格した．2006 年 10 月に初代松本博之名誉教授の後任として私が京都大学より着任した．2018 年 8 月より診療科名を神経内科から脳神経内科へ変更した．

脳神経内科は，中枢神経（脳・脊髄），末梢神経，神経筋接合部，骨格筋の器質的疾患に対して診断治療を行う診療科である．脳血管障害や神経感染症などの迅速な対応が必要な急性疾患から，多くが難病である神経変性疾患，他疾患に伴う神経障害の診断と治療など全身にわたる広範囲な知識や診療技術が要求される分野である．脳神経内科疾患に対するより精緻な診断法と効果の高い治療法の構築のためには，病態解明や治療法開発のための基礎的研究が大変重要である．

本稿では，札幌医科大学の医学生や若い医師に少しでも参考になればと思い，私の脳神経内科疾患に対する研究の変遷について述べる．

1　大学院時代の研究（1983 年 4 月～ 1987 年 3 月）

私は，1981 年に京都大学医学部を卒業し，亀山正邦教授が主宰されていた神経内科教室に入局した．大学病院で 1 年，東京都養育院付属病院（現在の東京都健康長寿医療センター）で 1 年の研修を行い，1983 年に京都大学大学院医学研究科博士課程に入学した．亀山教授がこれからは痴呆（認知症）の研究が極めて重要になってくるとの助言をいただき，また，東京都養育院付属病院で多くの剖検脳の脳切に立ち会っていたので，認知症疾患である「アルツハイマー病」をテーマに研究することにした．1970 年代後半から 1980 年代

前半にかけて，アルツハイマー病の剖検脳を用いた生化学的研究から，アセチルコリン系の障害が認知機能低下と密接に関連しているとのコリン仮説が誕生していた時期であった．これまでの生化学的研究は神経伝達物質の変動を解析する研究が主体であったので，「アルツハイマー病における神経伝達物質受容体に関する研究」をテーマに研究を行った．神経内科教室で収集した剖検脳を用いて，実質的には京都大学医学部薬理学教室で研究を施行し，論文として発表した[1～5]．特に，ニコチン性受容体のダウンレギュレーションが認知機能の低下と相関することは，世界の研究者において検証された先駆的な研究成果となった．アルツハイマー病におけるニコチン性受容体の病態的意義と新たな予防・治療法開発に関する研究は，現在においても大きな研究テーマとなっている．

2　留学時代の研究（1987 年 4 月～ 1989 年 3 月）

医学博士を取得後，異国の地での留学を希望した．今と違いインターネットの無い時代であり，図書館の文献内容から留学先を検討し，手紙でポストドクトラルフェローとして受入可能であるかを問い合わせた．アルツハイマー病の研究を続けたいと思い，世界的に有名であったアルツハイマー病の臨床神経学者である Robert Katzman 教授と神経病理の大家である Robert Terry 教授がおられ，アルツハイマー病センターを持つ米国カリフォルニア大学サンディエゴ校医学部神経科学部門に留学することができた．直接のボスは Fred Gage 教授（現在，Salk Institute 所長）で，遺伝子導入細胞の脳内移植により神経機能の回復を目指す研究（神経疾患に対する Gene Therapy）（図 1）ならびに神経可塑性の研究に従事した．また，同部門斉藤綱雄教授とアルツハイマー病の発症機構における Protein kinase C の役割などに関する研究に従事した[6～12]．基礎研究と共に米国における脳神経内科診療の実態およびアルツハイマー病センターで認知症診療における医師，心理士，看護師，ケースワーカー等によるチーム医療の大切さについて学ぶことができた．

3．留学帰国後の京都大学臨床神経学教室時代（1989 年 4 月～ 2006 年 9 月）

留学帰国後は米国のアイオワ大学医学部神経内科教授から京都大学医学部神経内科教授に異動された木村淳先生のもとで神経内科医員となり，臨床と共に研究を継続した．木村　淳教授の専門分野は臨床電気生理学を基盤とした末梢・筋疾患であったが，自由にこれまでの研究を続けることを許可してくれた．1990 年に神経化学研究室の責任者であった中村重信先生が広島大学医学部神経内科教授で異動されたために，34 歳の医員の立場で神経化学研究室の責任者となった．その後，助教，講師，助教授と昇任したが，多くの若者に声をかけて大学院生として研究室に入ってもらい，最終的に 25 名に医学博士の称号を取得させることができた．また，8 名が学位取得後海外留学を経験した．研究テーマは神経変性疾患を対象としたが，大学院生にそれまでの臨床研修で興味をもった疾患研究を自由に決めさせた．アルツハイマー病，パーキンソン病，および筋萎縮性側索硬化症（ALS）が研究対象となった．私がこれまで共同研究してきた京都大学薬学部や京都薬科大学の教室の教授と連携してその教室の若い大学院生やスタッフの方たちの力も借りて研究を進め



図 1. 神経疾患に対する Gene Therapy



図 2. アルツハイマー病に対する治療戦略

た．研究室の主催者として，科学研究費補助金などのグラントを獲得することに尽力した．

アルツハイマー病に関しては，アルツハイマー病脳で出現する老人斑や神経原線維変化の分子生物学的研究，家族性アルツハイマー病の原因遺伝子の発見，弧発性アルツハイマー病の危険因子としてのアポリポ蛋白 E-ε4 の同定などからアミロイドカスケード仮説が提唱されるようになっていた．そこで，研究戦略（図2）を構築し，治療に向けた研究を進めた．1）剖検脳を用いた病態生化学的研究として，①細胞の恒常性維持に重要な情報伝達分子の解析，②ニューロン変性過程への酸化ストレス，ミトコンドリア機能障害の関与，③ニューロン死へのアポトーシス機構の関与，④プロテオミクス研究，などを展開した[13~69]．2）神経保護治療候補物質の探索およびその作用機序の解明研究として，①ニコチン性受容体を介する神経保護治療の創生，②神経栄養因子やエストロゲンなどの神経保護作用の解明および新たな神経保護治療候補物質として牛血清中からセロフェンド酸を発見し，その作用機序について解明した[70~89]．3）ニューロン・グリア相関の研究として，グリア制御によるニューロン死の抑制・神経保護治療の創成研究を進めた[90~99]．4）家族性アルツハイマー病原因遺伝子の機能解析研究として，家族性アルツハイマー病の原因遺伝子蛋白であるアミロイド前駆体蛋白質やプレセニリン蛋白質の機能解析を行った[100~109]．5）発症因子の研究として，遺伝因子の解析を進めた[110~116]．剖検脳に関しては海外のケースウェスタンリザーブ大学医学部の Peter Whitehouse 教授と George Perry 教授の協力を得て，提供していただいた．以上の成果を基に，「アルツハイマー病のタンパク質分子レベルにおける研究」および「脳アミロイドーシス予防・治療薬のスクリーニング方法」で特許出願した．

パーキンソン病に関しては，1）パーキンソン病における選択的中脳ドーパミンニューロン死および封入体形成機序の解明，2）ドーパミン代謝に関する研究，3）パーキンソン病モデル作製による神経保護治療候補物質の探索及びその作用機序の解明，4）パーキンソン病に対する再生医療研究を進めた[117~152]．一方，点眼薬を用いた瞳孔散大筋機能評価におけるパーキンソン病と他類似疾患の鑑別に関する臨床試験を行い[153]，「パーキンソン病診断キットおよびパーキンソン病診断方法」で特許出願した．

筋萎縮性側索硬化症（ALS）に関しては，1）ALS における選択的脊髄運動ニューロン死の発症機序の解明，2）ALS モデル作製による神経保護治療候補物質の探索およびその作用機序の解明，3）ALS に対する臨床的ヒト遺伝子解析研究などを進めた[154~167]．

研究を遂行するためには，研究資金が必要となる．研究成果を論文として発表し，科学研究費補助金などの研究グラントの獲得に尽力した．この期間に，科学研究費補助金の研究代表者として，基盤研究 A　1 件，基盤研究 B　3 件，基盤研究 C　1 件，萌芽研究　5 件，重点領域研究　3 件，特定領域研究 A　3 件，特定領域研究 C　5 件を獲得した．研究分担者として，基盤研究 A　2 件，基盤研究 B　1 件，重点領域研究　2 件，特定領域研究 A　1 件，基盤研究 C　5 件を獲得した．

4. 札幌医科大学へ異動後（2006 年 10 月～現在）

2006 年 10 月に初代松本博之名誉教授の後任として私が京都大学より着任した．教室には分子生物学・細胞生物学的研究に必要な機器がなかったので，京都大学から貸借の形で研究機器を移動させて，研究を進めることにした．

1）分子神経科学的研究

アルツハイマー病やパーキンソン病のモデル動物を作製し，その分子病態解明やその制御法の確立を目指し，国内外の最先端の研究室との共同研究を推進させている．最近は，ミクログリアの病態における役割に着目し，ミクログリア制御による神経変性疾患治療の開発を目指している．また，骨髄間葉系幹細胞などを



図 3. 神経変性疾患に対する予防・治療法の方向性

用いた神経再生治療法の開発に取組んでいる．ヒストン脱アセチル化酵素 SIRT1 が神経幹細胞に発現が強く神経細胞への分化を正に制御しうる重要な知見を見出しており，細胞の生存にも大きな役割を果たしていることを明らかにし，将来的に多発性硬化症や神経変性疾患の治療戦略の応用に寄与する可能性を検討している（図 3）[168~220]．

2）臨床神経生理学的研究

重症筋無力症 (MG) などにみられる筋疲労の発症機序として従来の神経筋接合部のシナプス接続の障害以外に，興奮収縮連関（Excitation-Contraction coupling, EC-coupling）の障害を想定して研究を進め，MG においては EC coupling の障害を明らかにし，同部位の免疫学的治療により MG 症状が改善される機序の解明を進めている[221~229]．

3）臨床研究

脳卒中研究として，神経超音波の臨床研究と頸動脈狭窄症に対する血管内治療研究を行っている．また，過疎の進む地域における脳卒中医療の質の向上を目指して，医療従事者の脳卒中医療と教育の実態調査などを行い，行政に発信するとともに，脳卒中と認知症に加えて，動脈硬化リスク管理を含めた IT を活用した医療連携システム（DASCH システム：Databank of Stroke Care in Hokkaido）の構築を進めている．また，神経変性疾患伴う呼吸障害の緩和に対する研究は伝統的に継続されており，ALS や多系統萎縮症（MSA）の呼吸不全における非侵襲的呼吸療法の検討を行っている．一方，健常高齢者，軽度認知障害，軽症アルツハイマー病の方を対象とした全国規模の追跡研究「J-ADNI (Japanese Alzheimer's Disease Neuroimaging) 臨床研究」に札幌医科大学は北海道では唯一の施設として参加し，アルツハイマー病治療薬の実用化を早めるために尽力した．現在，AMED 関連でアルツハイマー病，多系統萎縮症，筋萎縮性側索硬化症，多発性硬化症などの臨床研究を進めている．

研究を遂行するためには科学研究費補助金などの研究グラントの獲得が重要であることを教室員に教えてきた．科学研究費補助金の研究代表者として，基盤研究 B　2 件，挑戦的萌芽研究　1 件を獲得した．研究分担者として，基盤研究 B　1 件，基盤研究 C　6 件を獲得した．また，若手教室員が，若手研究 B　4 件，挑戦的萌芽研究　2 件を獲得している．

おわりに

脳神経内科が対象とする疾患は，脳・脊髄・末梢神経・筋肉の疾患と広範に及ぶ．近年，人口の高齢化に伴い，介護を必要とする老年者が急増しており，社会問題となっている．その要因として脳卒中やアルツハイマー病などの認知症あるいはパーキンソン病など神経変性疾患の増加が挙げられる．脳神経内科疾患の克服のために，札幌医科大学医学部神経内科学講座が，今後も最先端の研究を幅広く推進させていくことを教室の目標として取組むことを期待する．

謝辞

これまで私と共に楽しく研究活動をしていただいた下記の研究者に心より感謝申しあげます（敬称を略させていただきます）．

京都大学医学研究科臨床神経学：故亀山正邦，中村重信，木村　淳，柴崎　浩，高橋良輔，辻　輝之，松島秀行，澤田秀行，川又　純，河崎洋志，長谷川浩史，井村徹也，木原武士，漆谷　真，景山　卓，大江田知子，山本兼司，本田和弘，北川尚之，河野隆一，中溝知樹，植村健吾，塩崎愛子，神吉理枝，山下博史，葛谷　聡，

山川健太郎，竹内啓喜，青柳信寿，渡邉　究，浅田めぐみ，今井久美子
札幌医科大学医学部神経内科学講座：川又　純，久原真，齊藤正樹，鈴木秀一郎，松村晃寛，松下隆司，眞部健郎，岩原直敏，齋藤太郎，藤倉　舞，横川和樹，鈴木紘美，今井富裕，保月隆良，山内理香，津田笑子，豊島貴信，外山祐一郎，倉内麗徳，中村祐貴，雨宮葉子，小松崎陽子
札幌医科大学医学部神経科学講座：長峯　隆，鈴木鮎子（名古屋市立大学脳神経内科）
北海道医療大学：藤井博匡，江本美穂
京都大学医学部薬理学教室：故藤原元始，塚原徹也，二宮治明
京都大学薬学研究科：赤池昭紀および研究室員，杉本八郎
京都薬科大学病態生理学：谷口隆之および研究室員，北村佳久，高田和幸
京都薬科大学衛生化学：藤本貞毅および研究室員
京都大学医学研究科人間健康科学系：木下彩栄および研究室員，前迫真人
東京大学医科学研究所細胞生物化学研究部：竹縄忠臣
University of California, San Diego：
Fred H. Gage，故斉藤綱男，故 Robert Katzman，故 Robert D. Terry，故 Leon Thal，故 Wigbert C. Wiederholt，Eliezer Masliah，Greg Cole，Mark H. Tuszynski
Case Western Reserve University：
Peter J. Whitehouse，George Perry & his laboratory members，故 Mark A. Smith
National Hospital for Neurology and Neurosurgery, Queen Square：
Martin Rossor

文献

1） Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Biochemical characterization of the nicotinic cholinergic receptors in human brain: binding of (-)-[3H]nicotine. J Neurochem 1985; 45: 604-610.
2） Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 1986; 46: 288-293.
3） Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J Neurochem 1986; 47: 1295-1301.
4） Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia. J Neurochem 1987; 48: 1215-1221.
5） Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 1988; 23: 404-406.
6） Shimohama S, Rosenberg MB, Fagan AM, Wolff JA, Short MP, Breakefield XO, Friedmann T, Gage FH. Grafting genetically modified cells into the rat brain: characteristics of E. coli beta-galactosidase as a reporter gene. Brain Res Mol Brain Res 1989; 5: 271-278.
7） Wolff JA, Fisher LJ, Xu L, Jinnah HA, Langlais PJ, Iuvone PM, O'Malley KL, Rosenberg MB, Shimohama S, Friedmann T, et al. Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 1989; 86: 9011-9014.
8） Shimohama S, Saitoh T, Gage FH. Differential expression of protein kinase C isozymes in rat cerebellum. J Chem Neuroanat 1990; 3: 367-375.
9） Masliah E, Cole G, Shimohama S, Hansen L, DeTeresa R, Terry RD, Saitoh T. Differential involvement of protein kinase C isozymes in Alzheimer‘s disease. J Neurosci 1990; 10: 2113-2124.
10） Masliah E, Yoshida K, Shimohama S, Gage FH, Saitoh T. Differential expression of protein kinase C isozymes in rat glial cell cultures. Brain Res 1991; 549: 106-111.
11） Shimohama S, Saitoh T, Gage FH. Changes in protein kinase C isozymes in the rat hippocampal formation following hippocampal lesion. Hippocampus 1993; 3: 43-55.
12） Shimohama S, Saitoh T. Differential expression of protein kinase C -alpha and -betall in rat septum and changes following fimbria-fornix lesion. Brain Res 1998; 781: 343-347.
13） Ninomiya H, Fukunaga R, Taniguchi T, Fujiwara M, Shimohama S, Kameyama M. [3H]N-[1-(2-thienyl)cyclohexyl]-3,4-piperidine ([3H]TCP) binding in human frontal cortex: decreases in Alzheimer-type dementia. J Neurochem 1990; 54: 526-532.
14） Shimohama S, Homma Y, Suenaga T, Fujimoto S, Taniguchi T, Araki W, Yamaoka Y, Takenawa T, Kimura J. Aberrant accumulation of phospholipase C-delta in Alzheimer brains. Am J Pathol 1991; 139: 737-742.
15） Shimohama S, Suenaga T, Araki W, Yamaoaka Y, Shimizu K, Kimura J. Presence of calpain II immunoreactivity in senile plaques in Alzheimer's disease. Brain Res 1991; 558: 105-108.
16） Shimohama S, Fujimoto S, Taniguchi T, Kimura J. Phosphatidylinositol-specific phospholipase C activity in the postmortem human brain: no alteration in Alzheimer's disease. Brain Res 1992; 579: 347-349.
17） Shimohama S, Narita M, Matsushima H, Kimura J, Kameyama M, Hagiwara M, Hidaka H, Taniguchi T. Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. Neurology 1993; 43: 1407-1413.
18） Shimohama S, Fujimoto S, Taniguchi T, Kameyama M, Kimura J. Reduction of low-molecular-weight acid phosphatase activity in Alzheimer brains. Ann Neurol 1993; 33: 616-621.
19） Matsushima H, Shimohama S, Yamaoka Y, Kimura J, Taniguchi T, Hagiwara M, Hidaka H. Alteration of human platelet protein

kinase C with normal aging. Mech Ageing Dev 1993; 69: 129-136.

20) Shimohama S, Perry G, Richey P, Takenawa T, Whitehouse PJ, Miyoshi K, Suenaga T, Matsumoto S, Nishimura M, Kimura J. Abnormal accumulation of phospholipase C-delta in filamentous inclusions of human neurodegenerative diseases. Neurosci Lett 1993; 162: 183-186.

21) Matsushima H, Shimohama S, Tanaka S, Taniguchi T, Hagiwara M, Hidaka H, Kimura J. Platelet protein kinase C levels in Alzheimer's disease. Neurobiol Aging 1994; 15: 671-674.

22) Shimohama S, Perry G, Richey P, Praprotnik D, Takenawa T, Fukami K, Whitehouse PJ, Kimura J. Characterization of the association of phospholipase C-delta with Alzheimer neurofibrillary tangles. Brain Res 1995; 669: 217-224.

23) Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J. Reduction of platelet phospholipase C activity in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1995; 9: 213-217.

24) Shimohama S, Fujimoto S, Matsushima H, Takenawa T, Taniguchi T, Perry G, Whitehouse PJ, Kimura J. Alteration of phospholipase C-delta protein level and specific activity in Alzheimer's disease. J Neurochem 1995; 64: 2629-2634.

25) Shimohama S, Fujimoto S, Chachin M, Taniguchi T, Perry G, Whitehouse PJ, Kimura J. Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease. Brain Res 1995; 699: 125-129.

26) Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J. Changes in platelet phospholipase C protein level and activity in Alzheimer's disease. Neurobiol Aging 1995; 16: 895-900.

27) Shimohama S, Chachin M, Taniguchi T, Hidaka H, Kimura J. Changes of neurocalcin, a calcium-binding protein, in the brain of patients with Alzheimer's disease. Brain Res 1996; 716: 233-236.

28) Matsushima H, Shimohama S, Chachin M, Taniguchi T, Kimura J. Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease. J Neurochem 1996; 67: 317-323.

29) Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T. Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 1997; 232: 418-421.

30) Bodick N, Forette F, Hadler D, Harvey RJ, Leber P, McKeith IG, Riekkinen PJ, Rossor MN, Scheltens P, Shimohama S, Spiegel R, Tanaka S, Thal LJ, Urata Y, Whitehouse P, Wilcock G. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis Assoc Disord 1997; 11(Suppl 3): 50-53.

31) Thal LJ, Carta A, Doody R, Leber P, Mohs R, Schneider L, Shimohama S, Silber C. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11(Suppl 3): 46-49.

32) Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem Biophys Res Commun 1997; 236: 239-242.

33) Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, Taniguchi T. Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer's disease brains. Neurosci Lett 1997; 237: 17-20.

34) Shimohama S, Sumida Y, Fujimoto S, Matsuoka Y, Taniguchi T, Takenawa T, Kimura J. Differential expression of rat brain phospholipase C isozymes in development and aging. Biochem Biophys Res Commun 1998; 243: 210-216.

35) Shimohama S, Sasaki Y, Fujimoto S, Kamiya S, Taniguchi T, Takenawa T, Kimura J. Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease. Neuroscience 1998; 82: 999-1007.

36) Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, Smith MA, Perry G, Whitehouse PJ, Taniguchi T. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 1998; 780: 260-269.

37) Shimohama S, Tanino H, Sumida Y, Tsuda J, Fujimoto S. Alteration of myo-inositol monophosphatase in Alzheimer's disease brains. Neurosci Lett 1998; 245: 159-162.

38) Tsuji T, Shimohama S, Kimura J, Shimizu K. m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neurosci Lett 1998; 248: 109-112.

39) Shimohama S, Fujimoto S, Sumida Y, Tanino H. Differential expression of rat brain bcl-2 family proteins in development and aging. Biochem Biophys Res Commun 1998; 252: 92-96.

40) Shimohama S, Fujimoto S, Sumida Y, Akagawa K, Shirao T, Matsuoka Y, Taniguchi T. Differential expression of rat brain synaptic proteins in development and aging. Biochem Biophys Res Commun 1998; 251: 394-398.

41) Matsushima H, Shimohama S, Kawamata J, Fujimoto S, Takenawa T, Kimura J. Reduction of platelet phospholipase C-delta1 activity in Alzheimer's disease associated with a specific apolipoprotein E genotype (epsilon3/epsilon3). Int J Mol Med 1998; 1: 91-93.

42) Shimohama S, Kamiya S, Taniguchi T, Kimura J. Intracellular receptors for activated C-kinase in the postmortem human brain: no alteration in Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 384-386.

43) Kitamura Y, Shimohama S, Koike H, Kakimura Ji, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 1999; 254: 582-586.

44) Shimohama S, Tanino H, Fujimoto S. Changes in caspase expression in Alzheimer's disease: comparison with development and aging. Biochem Biophys Res Commun 1999; 256: 381-384.

45) Hattori N, Kitagawa K, Higashida T, Yagyu K, Shimohama S, Wataya T, Perry G, Smith MA, Inagaki C. CI-ATPase

and Na+/K(+)-ATPase activities in Alzheimer's disease brains. Neurosci Lett 1998; 254: 141-144.

46) Shimohama S, Kamiya S, Taniguchi T, Sumida Y, Fujimoto S. Differential involvement of small G proteins in Alzheimer's disease. Int J Mol Med 1999; 3: 597-600.

47) Tsuji T, Shimohama S, Kamiya S, Sazuka T, Ohara O. Analysis of brain proteins in Alzheimer's disease using high-resolution two-dimensional gel electrophoresis. J Neurol Sci 1999; 166: 100-106.

48) Imura T, Shimohama S, Sato M, Nishikawa H, Madono K, Akaike A, Kimura J. Differential expression of small heat shock proteins in reactive astrocytes after focal ischemia: possible role of beta-adrenergic receptor. J Neurosci 1999; 19: 9768-9779.

49) Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 2000; 273: 5-9.

50) Shimohama S. Apoptosis in Alzheimer's disease--an update. Apoptosis 2000; 5: 9-16. Review.

51) Kim HT, Russell RL, Raina AK, Harris PL, Siedlak SL, Zhu X, Petersen RB, Shimohama S, Smith MA, Perry G. Protein disulfide isomerase in Alzheimer disease. Antioxid Redox Signal 2000; 2: 485-489.

52) Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001; 21: 3017-3023.

53) Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-767.

54) Tsuji T, Shimohama S. Analysis of the proteomic profiling of brain tissue in Alzheimer's disease. Dis Markers 2001; 17: 247-257.

55) Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, Szweda LI, Kaminski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002 15; 277: 4644-4648.

56) Shimohama S, Tanino H, Fujimoto S. Differential expression of rat brain caspase family proteins during development and aging. Biochem Biophys Res Commun 2001; 289: 1063-1066.

57) Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith MA. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 2001; 79: 311-318.

58) Tsuji T, Shimohama S. Protein degradation in Alzheimer's disease and aging of the brain. Prog Mol Subcell Biol 2002; 29: 43-60. Review.

59) Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 2002; 27: 1245-1253.

60) Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, Shimohama S, Avila J, Castellani RJ, Smith MA. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 2002; 133: 507-513. Review.

61) Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS, Smith MA. Reactive oxygen: its sources and significance in Alzheimer disease. J Neural Transm Suppl 2002; (62): 69-75. Review.

62) Raina AK, Hochman A, Ickes H, Zhu X, Ogawa O, Cash AD, Shimohama S, Perry G, Smith MA. Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out? Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 251-254. Review.

63) Kitamura Y, Tsuchiya D, Takata K, Shibagaki K, Taniguchi T, Smith MA, Perry G, Miki H, Takenawa T, Shimohama S. Possible involvement of Wiskott-Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease. Neurosci Lett 2003; 346: 149-152.

64) Raina AK, Zhu X, Shimohama S, Perry G, Smith MA. Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept. Cell Biochem Biophys 2003; 39: 249-255. Review.

65) Shiozaki A, Tsuji T, Kohno R, Kawamata J, Uemura K, Teraoka H, Shimohama S. Proteome analysis of brain proteins in Alzheimer's disease: subproteomics following sequentially extracted protein preparation. J Alzheimers Dis 2004; 6: 257-268.

66) Zhu X, Wang Y, Ogawa O, Lee HG, Raina AK, Siedlak SL, Harris PL, Fujioka H, Shimohama S, Tabaton M, Atwood CS, Petersen RB, Perry G, Smith MA. Neuroprotective properties of Bcl-w in Alzheimer disease. J Neurochem 2004; 89: 1233-1240.

67) Liu Q, Smith MA, Avilá J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S, Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PL, Sayre LM, Perry G. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 2005; 38: 746-754.

68) Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreira PI, Miller FP, Nunomura A, Shimohama S, Perry G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 2005; 280: 20978-20986.

69) Tsuchiya D, Kitamura Y, Takata K, Sugisaki T, Taniguchi T, Uemura K, Miki H, Takenawa T, Shimohama S. Developmental expression of neural Wiskott-Aldrich syndrome protein (N-WASP) and WASP family verprolin-homologous protein (WAVE)-related proteins in postnatal rat cerebral cortex and hippocampus. Neurosci Res 2006; 56: 459-469.

70) Shimohama S, Ogawa N, Tamura Y, Akaike A, Tsukahara

T, Iwata H, Kimura J. Protective effect of nerve growth factor against glutamate-induced neurotoxicity in cultured cortical neurons. Brain Res 1993; 632: 296-302.

71) Shimohama S, Tamura Y, Akaike A, Tsukahara T, Ohara O, Watanabe S, Kimura J. Brain-derived neurotrophic factor pretreatment exerts a partially protective effect against glutamate-induced neurotoxicity in cultured rat cortical neurons. Neurosci Lett 1993; 164: 55-58.

72) Akaike A, Tamura Y, Yokota T, Shimohama S, Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 1994; 644: 181-187.

73) Tsukahara T, Takeda M, Shimohama S, Ohara O, Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-t etrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 1995; 37: 733-739; discussion 739-741.

74) Shimohama S, Akaike A, Tamura Y, Matsushima H, Kume T, Fujimoto S, Takenawa T, Kimura J. Glutamate-induced antigenic changes of phospholipase C-delta in cultured cortical neurons. J Neurosci Res 1995; 41: 418-426.

75) Shimohama S, Akaike A, Kimura J. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation. Ann N Y Acad Sci 1996; 777: 356-361.

76) Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S, Kimura J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res 1997; 765: 135-140.

77) Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997; 42: 159-163.

78) Kume T, Kouchiyama H, Kaneko S, Maeda T, Kaneko S, Akaike A, Shimohama S, Kihara T, Kimura J, Wada K, Koizumi S. BDNF prevents NO mediated glutamate cytotoxicity in cultured cortical neurons. Brain Res 1997; 756: 200-204.

79) Shimohama S, Greenwald DL, Shafron DH, Akaika A, Maeda T, Kaneko S, Kimura J, Simpkins CE, Day AL, Meyer EM. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 1998; 779: 359-363.

80) Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 1998; 792: 331-334.

81) Honda K, Sawada H, Kihara T, Urushitani M, Nakamizo T, Akaike A, Shimohama S. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J Neurosci Res 2000; 60: 321-327.

82) Kume T, Nishikawa H, Tomioka H, Katsuki H, Akaike A, Kaneko S, Maeda T, Kihara T, Shimohama S. p75-mediated neuroprotection by NGF against glutamate cytotoxicity in cortical cultures. Brain Res 2000; 852: 279-289.

83) Kihara T, Shimohama S, Akaike A. Effects of nicotinic receptor agonists on beta-amyloid beta-sheet formation. Jpn J Pharmacol 1999; 79: 393-396.

84) Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 2001; 276: 13541-13546.

85) Shimohama S, Kihara T. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol Psychiatry 2001; 49: 233-239. Review.

86) Honda K, Shimohama S, Sawada H, Kihara T, Nakamizo T, Shibasaki H, Akaike A. Nongenomic antiapoptotic signal transduction by estrogen in cultured cortical neurons. J Neurosci Res 2001; 64: 466-475.

87) Kume T, Asai N, Nishikawa H, Mano N, Terauchi T, Taguchi R, Shirakawa H, Osakada F, Mori H, Asakawa N, Yonaga M, Nishizawa Y, Sugimoto H, Shimohama S, Katsuki H, Kaneko S, Akaike A. Isolation of a diterpenoid substance with potent neuroprotective activity from fetal calf serum. Proc Natl Acad Sci U S A 2002; 99: 3288-3293.

88) Takata K, Kitamura Y, Kakimura J, Shibagaki K, Taniguchi T, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Possible protective mechanisms of heme oxygenase-1 in the brain. Ann N Y Acad Sci 2002; 977: 501-506.

89) Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Kanki R, Yamashita H, Akaike A. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res 2002; 70: 274-282.

90) Imura T, Shimohama S. Opposing effects of adenosine on the survival of glial cells exposed to chemical ischemia. J Neurosci Res 2000; 62: 539-546.

91) Kakimura J, Kitamura Y, Taniguchi T, Shimohama S, Gebicke-Haerter PJ. Bip/GRP78-induced production of cytokines and uptake of amyloid-beta(1-42) peptide in microglia. Biochem Biophys Res Commun 2001; 281: 6-10.

92) Kakimura J, Kitamura Y, Takata K, Umeki M, Suzuki S, Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ, Smith MA, Perry G, Shimohama S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J 2002; 16: 601-603.

93) Kitamura Y, Shibagaki K, Takata K, Tsuchiya D, Taniguchi T, Gebicke-Haerter PJ, Miki H, Takenawa T, Shimohama S. Involvement of Wiskott-Aldrich syndrome protein family verprolin-homologous protein (WAVE) and Rac1 in the phagocytosis of amyloid-beta(1-42) in rat microglia. J Pharmacol Sci 2003; 92: 115-123.

94) Takata K, Kitamura Y, Tsuchiya D, Kawasaki T, Taniguchi T, Shimohama S. Heat shock protein-90-induced microglial clearance of exogenous amyloid-beta1-42 in rat hippocampus in vivo. Neurosci Lett 2003; 344: 87-90.

95) Takata K, Kitamura Y, Kakimura J, Shibagaki K, Tsuchiya D, Taniguchi T, Smith MA, Perry G, Shimohama S. Role of high mobility group protein-1 (HMG1) inamyloid-beta homeostasis. Biochem Biophys Res Commun 2003; 301: 699-703.

96) Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, Shimohama S. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 2004; 325: 976-982.

97) Takata K, Kitamura Y, Tsuchiya D, Kawasaki T, Taniguchi T, Shimohama S. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res 2004; 78: 880-891.

98) Kitamura Y, Yanagisawa D, Inden M, Takata K, Tsuchiya D, Kawasaki T, Taniguchi T, Shimohama S. Recovery of focal brain ischemia-induced behavioral dysfunction by intracerebroventricular injection of microglia. J Pharmacol Sci 2005; 97: 289-293.

99) Takata K, Kitamura Y, Yanagisawa D, Morikawa S, Morita M, Inubushi T, Tsuchiya D, Chishiro S, Saeki M, Taniguchi T, Shimohama S, Tooyama I. Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS Lett 2007; 581: 475-478.

100) Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 1991; 181: 265-271.

101) Kitagawa N, Shimohama S, Oeda T, Uemura K, Kohno R, Kuzuya A, Shibasaki H, Ishii N. The role of the presenilin-1 homologue gene sel-12 of Caenorhabditis elegans in apoptotic activities. J Biol Chem 2003; 278: 12130-12134.

102) Uemura K, Kitagawa N, Kohno R, Kuzuya A, Kageyama T, Shibasaki H, Shimohama S. Presenilin 1 mediates retinoic acid-induced differentiation of SH-SY5Y cells through facilitation of Wnt signaling. J Neurosci Res 2003; 73: 166-175.

103) Uemura K, Kitagawa N, Kohno R, Kuzuya A, Kageyama T, Chonabayashi K, Shibasaki H, Shimohama S. Presenilin 1 is involved in maturation and trafficking of N-cadherin to the plasma membrane. J Neurosci Res 2003; 74: 184-191.

104) Uemura K, Kuzuya A, Shimohama S. Protein trafficking and Alzheimer's disease. Curr Alzheimer Res 2004; 1: 1-10. Review.

105) Uemura K, Kihara T, Kuzuya A, Okawa K, Nishimoto T, Bito H, Ninomiya H, Sugimoto H, Kinoshita A, Shimohama S. Activity-dependent regulation of beta-catenin via epsilon-cleavage of N-cadherin. Biochem Biophys Res Commun 2006; 345: 951-958.

106) Uemura K, Kihara T, Kuzuya A, Okawa K, Nishimoto T, Ninomiya H, Sugimoto H, Kinoshita A, Shimohama S. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett 2006; 402: 278-283.

107) Tsuchiya D, Kitamura Y, Takata K, Taniguchi T, Uemura K, Miki H, Takenawa T, Shimohama S. Morphological change by overexpression of D385A dominant negative presenilin 1 in human neuroblastoma SH-SY5Y cells. J Pharmacol Sci 2006; 102: 354-358.

108) Kuzuya A, Uemura K, Kitagawa N, Aoyagi N, Kihara T, Ninomiya H, Ishiura S, Takahashi R, Shimohama S. Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). J Neurosci Res 2007; 85: 153-165.

109) Uemura K, Kuzuya A, Shimozono Y, Aoyagi N, Ando K, Shimohama S, Kinoshita A. GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem 2007; 282: 15823-15832.

110) Uemura K, Kuzuya A, Aoyagi N, Ando K, Shimozono Y, Ninomiya H, Shimohama S, Kinoshita A. Amyloid beta inhibits ectodomain shedding of N-cadherin via down-regulation of cell-surface NMDA receptor. Neuroscience 2007; 145: 5-10.

111) Kawamata J, Tanaka S, Shimohama S, Ueda K, Kimura J. Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. J Neurol Neurosurg Psychiatry 1994; 57: 1414-1416.

112) Kawamata J, Hasegawa H, Shimohama S, Kimura J, Tanaka S, Ueda K. Leu106-->Val (CTC-->GTC) mutation of superoxide dismutase-1 gene in patient with familial amyotrophic lateral sclerosis in Japan. Lancet 1994; 343: 1501.

113) Shimohama S, Kamiya S, Fujii M, Ogawa T, Kanamori M, Kawamata J, Imura T, Taniguchi T, Yagisawa H. Mutation in the pleckstrin homology domain of the human phospholipase C-delta 1 gene is associated with loss of function. Biochem Biophys Res Commun 1998; 245: 722-728.

114) Tanaka S, Kawamata J, Shimohama S, Akaki H, Akiguchi I, Kimura J, Ueda K. Inferior temporal lobe atrophy and APOE genotypes in Alzheimer's disease. X-ray computed tomography, magnetic resonance imaging and Xe-133 SPECT studies. Dement Geriatr Cogn Disord 1998; 9: 90-98.

115) Akatsu H, Yamagata HD, Kawamata J, Kamino K, Takeda M, Yamamoto T, Miki T, Tooyama I, Shimohama S, Kosaka K. Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan. Dement Geriatr Cogn Disord 2006; 22: 216-222.

116) Kawamata J, Shimohama S. Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease. J Alzheimers Dis 2002; 4: 71-76.

117) Sawada H, Shimohama S, Kawamura T, Akaike A, Kitamura Y, Taniguchi T, Kimura J. Mechanism of resistance to NO-induced neurotoxicity in cultured rat dopaminergic neurons. J Neurosci Res 1996; 46: 509-518.

118) Sawada H, Kawamura T, Shimohama S, Akaike A, Kimura J. Different mechanisms of glutamate-induced neuronal death between dopaminergic and non-dopaminergic neurons in rat mesencephalic culture. J Neurosci Res 1996; 43: 503-510.

119) Sawada H, Shimohama S, Tamura Y, Kawamura T, Akaike A, Kimura J. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J Neurosci Res 1996; 43: 55-62.

120) Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A,

Kimura J, Shimohama S. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998; 44: 110-119.

121) Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J Neurosci Res 1998; 54: 707-719.

122) Ibi M, Sawada H, Kume T, Katsuki H, Kaneko S, Shimohama S, Akaike A. Depletion of intracellular glutathione increases susceptibility to nitric oxide in mesencephalic dopaminergic neurons. J Neurochem 1999; 73: 1696-1703.

123) Sawada H, Ibi M, Kihara T, Urushitani M, Honda K, Nakanishi M, Akaike A, Shimohama S. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J 2000; 14: 1202-1214.

124) Sawada H, Ibi M, Kihara T, Urushitani M, Nakanishi M, Akaike A, Shimohama S. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J Neurochem 2000; 74: 1175-1184.

125) Sawada H, Shimohama S. Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neurosci Biobehav Rev 2000; 24: 143-147. Review.

126) Kageyama T, Oeda T, Imura T, Kawamata J, Suzuki S, Tomimoto H, Shimohama S. Coexistence of expanded CAG repeats in the MJD1a and DRPLA genes. Neurology 2000; 54: 265-266.

127) Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res 2000; 879: 115-121.

128) Kageyama T, Imura T, Matsuo A, Minato N, Shimohama S. Distribution of the 4F2 light chain, LAT1, in the mouse brain. Neuroreport 2000; 11: 3663-3666.

129) Ibi M, Sawada H, Nakanishi M, Kume T, Katsuki H, Kaneko S, Shimohama S, Akaike A. Protective effects of 1 alpha, 25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001; 40: 761-771.

130) Kitamura Y, Ishida Y, Takata K, Kakimura J, Mizutani H, Shimohama S, Akaike A, Taniguchi T. Alpha-synuclein protein is not scavenged in neuronal loss induced by kainic acid or focal ischemia. Brain Res 2001; 898: 181-185.

131) Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, Zhang J, Montine T, Sayre LM, Smith MA. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 2002; 319: 25-28.

132) Sawada H, Ibi M, Kihara T, Honda K, Nakamizo T, Kanki R, Nakanishi M, Sakka N, Akaike A, Shimohama S. Estradiol protects dopaminergic neurons in a MPP+Parkinson's disease model. Neuropharmacology 2002; 42: 1056-1064.

133) Kitamura Y, Inden M, Sanada H, Takata K, Taniguchi T, Shimohama S, Orii H, Mochii M, Agata K, Watanabe K. Inhibitory effects of antiparkinsonian drugs and caspase inhibitors in a parkinsonian flatworm model. J Pharmacol Sci 2003; 92: 137-142.

134) Sawada H, Shimohama S. Estrogens and Parkinson disease: novel approach for neuroprotection. Endocrine 2003; 21: 77-79. Review.

135) Kitamura Y, Taniguchi T, Shimohama S, Akaike A, Nomura Y. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem Res 2003; 28: 1035-1040.

136) Sakka N, Sawada H, Izumi Y, Kume T, Katsuki H, Kaneko S, Shimohama S, Akaike A. Dopamine is involved in selectivity of dopaminergic neuronal death by rotenone. Neuroreport 2003; 14: 2425-2428.

137) Shimohama S, Sawada H, Kitamura Y, Taniguchi T. Disease model: Parkinson's disease. Trends Mol Med 2003; 9: 360-365. Review.

138) Kohno R, Sawada H, Kawamoto Y, Uemura K, Shibasaki H, Shimohama S. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochem Biophys Res Commun 2004; 318: 113-118.

139) Sawada H, Kohno R, Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T, Yamakawa K, Shibasaki H, Yamamoto N, Akaike A, Inden M, Kitamura Y, Taniguchi T, Shimohama S. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem 2004; 279: 10710-10719.

140) Inden M, Kim D, Gu Y, Kitamura Y, Kondo J, Tsuchiya D, Taniguchi T, Shimohama S, Akaike A, Sumi S, Inoue K. Pharmacological characteristics of rotational behavior in hemiparkinsonian rats transplanted with mouse embryonic stem cell-derived neurons. J Pharmacol Sci 2004; 96: 53-64.

141) Izumi Y, Sawada H, Sakka N, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly. J Neurosci Res 2005; 79: 849-860.

142) Inden M, Kondo J, Kitamura Y, Takata K, Nishimura K, Taniguchi T, Sawada H, Shimohama S. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J Pharmacol Sci. 2005; 97: 203-211.

143) Inden M, Kitamura Y, Kondo J, Hayashi K, Yanagida T, Takata K, Tsuchiya D, Yanagisawa D, Nishimura K, Taniguchi T, Shimohama S, Sugimoto H, Akaike A. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats. J Neurochem 2005; 95: 950-961.

144) Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells. J Neurosci Res 2005; 82: 126-137.

145) Inden M, Kim DH, Qi M, Kitamura Y, Yanagisawa D, Nishimura K, Tsuchiya D, Takata K, Hayashi K, Taniguchi T, Yoshimoto K, Shimohama S, Sumi S, Inoue K. Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats. Neurosci Lett 2005; 387: 151-156.

146) Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol 2007; 557: 132-140.

147) Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, Akaike A. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 2007; 282: 4364-4372.

148) Yanagisawa D, Qi M, Kim DH, Kitamura Y, Inden M, Tsuchiya D, Takata K, Taniguchi T, Yoshimoto K, Shimohama S, Akaike A, Sumi S, Inoue K. Improvement of focal ischemia-induced rat dopaminergic dysfunction by striatal transplantation of mouse embryonic stem cells. Neurosci Lett 2006; 407: 74-79.

149) Inden M, Taira T, Kitamura Y, Yanagida T, Tsuchiya D, Takata K, Yanagisawa D, Nishimura K, Taniguchi T, Kiso Y, Yoshimoto K, Agatsuma T, Koide-Yoshida S, Iguchi-Ariga SM, Shimohama S, Ariga H. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol Dis 2006; 24: 144-158.

150) Nishimura K, Kitamura Y, Inoue T, Umesono Y, Sano S, Yoshimoto K, Inden M, Takata K, Taniguchi T, Shimohama S, Agata K. Reconstruction of dopaminergic neural network and locomotion function in planarian regenerates. Dev Neurobiol 2007; 67: 1059-1078.

151) Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007; 101: 1491-1504.

152) Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, Yamamoto N, Kihara T, Uemura K, Inoue H, Taniguchi T, Akaike A, Takahashi R, Shimohama S. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J Neurosci Res 2009; 87: 576-585.

153) Sawada H, Yamakawa K, Yamakado H, Hosokawa R, Ohba M, Miyamoto K, Kawamura T, Shimohama S. Cocaine and phenylephrine eye drop test for Parkinson disease. JAMA 2005; 293: 932-934.

154) Kawamata J, Shimohama S, Takano S, Harada K, Ueda K, Kimura J. Novel G16S (GGC-AGC) mutation in the SOD-1 gene in a patient with apparently sporadic young-onset amyotrophic lateral sclerosis. Hum Mutat 1997; 9: 356-358.

155) Urushitani M, Shimohama S, Kihara T, Sawada H, Akaike A, Ibi M, Inoue R, Kitamura Y, Taniguchi T, Kimura J. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann Neurol 1998; 44: 796-807.

156) Imura T, Shimohama S, Kawamata J, Kimura J. Genetic variation in the ciliary neurotrophic factor receptor alpha gene and familial amyotrophic lateral sclerosis. Ann Neurol 1998; 43: 275.

157) Nakamizo T, Urushitani M, Inoue R, Shinohara A, Sawada H, Honda K, Kihara T, Akaike A, Shimohama S. Protection of cultured spinal motor neurons by estradiol. Neuroreport 2000; 11: 3493-3497.

158) Urushitani M, Inoue R, Nakamizo T, Sawada H, Shibasaki H, Shimohama S. Neuroprotective effect of cyclic GMP against radical-induced toxicity in cultured spinal motor neurons. J Neurosci Res 2000; 61: 443-448.

159) Urushitani M, Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 71-81. Review.

160) Oeda T, Shimohama S, Kitagawa N, Kohno R, Imura T, Shibasaki H, Ishii N. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet 2001; 10: 2013-2023.

161) Urushitani M, Nakamizo T, Inoue R, Sawada H, Kihara T, Honda K, Akaike A, Shimohama S. N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. J Neurosci Res 2001; 63: 377-387.

162) Nakamizo T, Kawamata J, Yoshida K, Kawai Y, Kanki R, Sawada H, Kihara T, Yamashita H, Shibasaki H, Akaike A, Shimohama S. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J Neurosci Res 2003; 71: 485-495.

163) Kanki R, Nakamizo T, Yamashita H, Kihara T, Sawada H, Uemura K, Kawamata J, Shibasaki H, Akaike A, Shimohama S. Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons. Brain Res 2004; 1015: 73-81.

164) Kume T, Kawai Y, Yoshida K, Nakamizo T, Kanki R, Sawada H, Katsuki H, Shimohama S, Sugimoto H, Akaike A. Protective effect of serofendic acid on glutamate-induced neurotoxicity in rat cultured motor neurons. Neurosci Lett 2005; 383: 199-202.

165) Nakamizo T, Kawamata J, Yamashita H, Kanki R, Kihara T, Sawada H, Akaike A, Shimohama S. Stimulation of nicotinic acetylcholine receptors protects motor neurons. Biochem Biophys Res Commun 2005; 330: 1285-1289.

166) Yamashita H, Kawamata J, Okawa K, Kanki R, Nakamizo T, Hatayama T, Yamanaka K, Takahashi R, Shimohama S. Heat-shock protein 105 interacts with and suppresses aggregation of mutant Cu/Zn superoxide dismutase: clues

to a possible strategy for treating ALS. J Neurochem 2007; 102: 1497-1505.

167) Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, Nakano I, Aoki M, Tsuji S, Yuasa T, Takano H, Hayashi H, Kuzuhara S, Sobue G; Research Committee on the Neurodegenerative Diseases of Japan. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci 2009; 276: 163-169.

168) Yanagida T, Takeuchi H, Kitamura Y, Takata K, Minamino H, Shibaike T, Tsushima J, Kishimoto K, Yasui H, Taniguchi T, Shimohama S. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci Res 2008; 62: 254-261.

169) Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, Sato M, Horio Y. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci U S A 2008; 105: 15599-15604.

170) Uemura K, Lill CM, Banks M, Asada M, Aoyagi N, Ando K, Kubota M, Kihara T, Nishimoto T, Sugimoto H, Takahashi R, Hyman BT, Shimohama S, Berezovska O, Kinoshita A. N-cadherin-based adhesion enhances Abeta release and decreases Abeta42/40 ratio. J Neurochem 2009; 108: 350-360.

171) Matsumura A, Oda M, Hozuki T, Imai T, Shimohama S. Dural arteriovenous fistula in a case of dementia with bithalamic MR lesions. Neurology 2008; 71: 1553.

172) Yamakawa K, Izumi Y, Takeuchi H, Yamamoto N, Kume T, Akaike A, Takahashi R, Shimohama S, Sawada H. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun 2010; 391: 129-134.

173) Kawamata J, Ikeda A, Fujita Y, Usui K, Shimohama S, Takahashi R. Mutations in LGI1 gene in Japanese families with autosomal dominant lateral temporal lobe epilepsy: the first report from Asian families. Epilepsia 2010; 51: 690-693.

174) Takata K, Kitamura Y, Nakata Y, Matsuoka Y, Tomimoto H, Taniguchi T, Shimohama S. Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease. Am J Pathol 2009; 175: 17-24.

175) Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol Pharm Bull 2009; 32: 332-336. Review.

176) Sawada H, Oeda T, Yamamoto K, Kitagawa N, Mizuta E, Hosokawa R, Ohba M, Nishio R, Yamakawa K, Takeuchi H, Shimohama S, Takahashi R, Kawamura T. Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 2009; 16: 174-182.

177) Aoyagi N, Uemura K, Kuzuya A, Kihara T, Kawamata J, Shimohama S, Kinoshita A, Takahashi R. PI3K inhibition causes the accumulation of ubiquitinated presenilin 1 without affecting the proteasome activity. Biochem Biophys Res Commun 2010; 391: 1240-1245.

178) Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, Yamaguchi H, Shimohama S, Lee HG, Zhu X, Smith MA, Perry G. Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 2010; 37: 731-737.

179) Ando K, Uemura K, Kuzuya A, Maesako M, Asada-Utsugi M, Kubota M, Aoyagi N, Yoshioka K, Okawa K, Inoue H, Kawamata J, Shimohama S, Arai T, Takahashi R, Kinoshita A. N-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease. J Biol Chem 2011; 286: 7619-7628.

180) Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, Fujikawa Y, Maelicke A, Tomimoto H, Taniguchi T, Shimohama S. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem 2010; 285: 40180-40191.

181) Shen H, Kihara T, Hongo H, Wu X, Kem WR, Shimohama S, Akaike A, Niidome T, Sugimoto H. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br J Pharmacol 2010; 161: 127-39.

182) Hisahara S, Shimohama S. Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis 2010; 2011: 951709.

183) Hisahara S, Shimohama S. Dopamine receptors and Parkinson's disease. Int J Med Chem 2011; 2011: 403039. doi: 10.1155/2011/403039.

184) Matsushita T, Kibayashi T, Katayama T, Yamashita Y, Suzuki S, Kawamata J, Honmou O, Minami M, Shimohama S. Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neurosci Lett 2011; 502: 41-45.

185) Asada-Utsugi M, Uemura K, Noda Y, Kuzuya A, Maesako M, Ando K, Kubota M, Watanabe K, Takahashi M, Kihara T, Shimohama S, Takahashi R, Berezovska O, Kinoshita A. N-cadherin enhances APP dimerization at the extracellular domain and modulates Aβ production. J Neurochem 2011; 119: 354-363.

186) Okamoto Y, Shirakashi Y, Ihara M, Urushitani M, Oono M, Kawamoto Y, Yamashita H, Shimohama S, Kato S, Hirano A, Tomimoto H, Ito H, Takahashi R. Colocalization of 14-3-3 proteins with SOD1 in Lewy body-like hyaline inclusions in familial amyotrophic lateral sclerosis cases and the animal model. PLoS One 2011; 6: e20427. doi: 10.1371/journal.pone.0020427.

187) Kawamata J, Suzuki S, Shimohama S. Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models. Ther Adv Chronic Dis 2011; 2: 197-208.

188) Han M, Ohnishi H, Nonaka M, Yamauchi R, Hozuki T, Hayashi T, Saitoh M, Hisahara S, Imai T, Shimohama S, Mori M. Relationship between dysphagia and depressive states in patients with Parkinson's disease. Parkinsonism

Relat Disord 2011; 17: 437-439.

189) Kawamata J, Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2011; 24(Suppl 2): 95-109.

190) Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Koyano S, Momoo T, Yuasa H, Mitake S, Higashihara M, Kaida K, Yamamoto D, Hisahara S, Shimohama S, Nakae Y, Johkura K, Vernino S, Sobue G. The spectrum of clinicopathological features in pure autonomic neuropathy. J Neurol 2012; 259: 2067-2075.

191) Kawamata J, Suzuki S, Shimohama S. α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease. Curr Drug Targets 2012; 13: 623-630. Review.

192) Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Asada M, Watanabe K, Hayashida N, Ihara M, Ito H, Shimohama S, Kihara T, Kinoshita A. Environmental enrichment ameliorated high-fat diet-induced Aß deposition and memory deficit in APP transgenic mice. Neurobiol Aging 2012; 33: 1011.e11-23. doi: 10.1016/j.neurobiolaging.2011.10.028.

193) Takata K, Takada T, Ito A, Asai M, Tawa M, Saito Y, Ashihara E, Tomimoto H, Kitamura Y, Shimohama S. Microglial Amyloid-ß1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer's Disease. Int J Alzheimers Dis 2012; 2012: 685739.

194) Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Hayashida N, Asada-Utsugi M, Watanabe K, Uemura M, Kihara T, Takahashi R, Shimohama S, Kinoshita A. Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem 2012; 287: 23024-23033.

195) Maesako M, Uemura K, Kuzuya A, Sasaki K, Asada M, Watanabe K, Ando K, Kubota M, Akiyama H, Takahashi R, Kihara T, Shimohama S, Kinoshita A. Gain of function by phosphorylation in Presenilin 1-mediated regulation of insulin signaling. J Neurochem 2012; 121: 964-973.

196) Maesako M, Uemura K, Iwata A, Kubota M, Watanabe K, Uemura M, Noda Y, Asada-Utsugi M, Kihara T, Takahashi R, Shimohama S, Kinoshita A. Continuation of exercise is necessary to inhibit high fat diet-induced ß-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. PLoS One 2013; 8: e72796. doi: 10.1371/journal.pone.0072796.

197) Noda Y, Asada M, Kubota M, Maesako M, Watanabe K, Uemura M, Kihara T, Shimohama S, Takahashi R, Kinoshita A, Uemura K. Copper enhances APP dimerization and promotes Aß production. Neurosci Lett 2013; 547: 10-15.

198) Suzuki S, Kawamata J, Matsushita T, Matsumura A, Hisahara S, Takata K, Kitamura Y, Kem W, Shimohama S. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats. J Neurosci Res 2013; 91: 462-471.

199) Inden M, Takata K, Nishimura K, Kitamura Y, Ashihara E, Yoshimoto K, Ariga H, Honmou O, Shimohama S. Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice. J Neurosci Res 2013; 91: 62-72.

200) Yamauchi R, Imai T, Tsuda E, Hozuki T, Yamamoto D, Shimohama S. Respiratory insufficiency with preserved diaphragmatic function in amyotrophic lateral sclerosis. Intern Med 2014; 53: 1325-1331.

201) Maesako M, Uemura M, Tashiro Y, Sasaki K, Watanabe K, Noda Y, Ueda K, Asada-Utsugi M, Kubota M, Okawa K, Ihara M, Shimohama S, Uemura K, Kinoshita A. High Fat Diet Enhances ß-Site Cleavage of Amyloid Precursor Protein (APP) via Promoting ß-Site APP Cleaving Enzyme 1/Adaptor Protein 2/Clathrin Complex Formation. PLoS One 2015; 10: e0131199. doi: 10.1371/journal.pone.0131199.

202) Matsumura A, Emoto MC, Suzuki S, Iwahara N, Hisahara S, Kawamata J, Suzuki H, Yamauchi A, Sato-Akaba H, Fujii HG, Shimohama S. Evaluation of oxidative stress in the brain of a transgenic mouse model of Alzheimer disease by in vivo electron paramagnetic resonance imaging. Free Radic Biol Med 2015; 85: 165-173.

203) Kato T, Konishi Y, Shimohama S, Beach TG, Akatsu H, Tooyama I. Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients. Neurosci Lett 2015; 591: 19-24.

204) Niino M, Sato S, Fukazawa T, Yoshimura S, Hisahara S, Matsushita T, Isobe N, Yoshida K, Houzen H, Miyazaki Y, Shimohama S, Kikuchi S, Kira J. Latitude and HLA-DRB1 alleles independently affect the emergence of cerebrospinal fluid IgG abnormality in multiple sclerosis. Mult Scler 2015; 21: 1112-1120.

205) Suzuki S, Kawamata J, Iwahara N, Matsumura A, Hisahara S, Matsushita T, Sasaki M, Honmou O, Shimohama S. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats. Neurosci Lett 2015; 584: 276-281.

206) Jingami N, Asada-Utsugi M, Uemura K, Noto R, Takahashi M, Ozaki A, Kihara T, Kageyama T, Takahashi R, Shimohama S, Kinoshita A. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease. J Alzheimers Dis 2015; 45: 109-115.

207) Matsumura A, Suzuki S, Iwahara N, Hisahara S, Kawamata J, Suzuki H, Yamauchi A, Takata K, Kitamura Y, Shimohama S. Temporal changes of CD68 and α7 nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models. J Alzheimers Dis 2015; 44: 409-423.

208) Watanabe K, Uemura K, Asada M, Maesako M, Akiyama H, Shimohama S, Takahashi R, Kinoshita A. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. Mol Brain 2015; 8:82. doi: 10.1186/s13041-015-0174-2.

209) Miyazaki Y, Niino M, Kanazawa I, Suzuki M, Mizuno M,

Hisahara S, Fukazawa T, Takahashi E, Amino I, Ochi R, Nakamura M, Akimoto S, Minami N, Fujiki N, Doi S, Shimohama S, Terayama Y, Kikuchi S. Fingolimod suppresses bone resorption in female patients with multiple sclerosis. J Neuroimmunol; 298: 24-31.

210) Nakamura Y, Matsushita T, Sato S, Niino M, Fukazawa T, Yoshimura S, Hisahara S, Isobe N, Shimohama S, Watanabe M, Yoshida K, Houzen H, Miyazaki Y, Yamasaki R, Kikuchi S, Kira J; Japan Multiple Sclerosis Genetics Consortium. Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study. J Neuroinflammation 2016; 13: 239. doi: 10.1186/s12974-016-0695-3.

211) Saito Y, Akazawa-Ogawa Y, Matsumura A, Saigoh K, Itoh S, Sutou K, Kobayashi M, Mita Y, Shichiri M, Hisahara S, Hara Y, Fujimura H, Takamatsu H, Hagihara Y, Yoshida Y, Hamakubo T, Kusunoki S, Shimohama S, Noguchi N. Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients. Sci Rep 2016; 6: 30793. doi: 10.1038/srep30793.

212) Matsushima A, Matsushima J, Matsumoto A, Moriwaka F, Honma S, Itoh K, Yamada K, Shimohama S, Ohnishi H, Mori M. Analysis of resources assisting in coping with swallowing difficulties for patients with Parkinson's disease: a cross-sectional study. BMC Health Serv Res 2016; 16: 276. doi: 10.1186/s12913-016-1467-6.

213) Ito N, Kamiguchi K, Nakanishi K, Sokolovskya A, Hirohashi Y, Tamura Y, Murai A, Yamamoto E, Kanaseki T, Tsukahara T, Kochin V, Chiba S, Shimohama S, Sato N, Torigoe T. A novel nuclear DnaJ protein, DNAJC8, can suppress the formation of spinocerebellar ataxia 3 polyglutamine aggregation in a J-domain independent manner. Biochem Biophys Res Commun 2016; 474: 626-633.

214) Inden M, Takata K, Yanagisawa D, Ashihara E, Tooyama I, Shimohama S, Kitamura Y. α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior. Neurochem Int 2016; 94: 74-81.

215) Matsushima A, Matsumoto A, Moriwaka F, Honma S, Itoh K, Yamada K, Shimohama S, Ohnishi H, Matsushima J, Mori M. A Cross-Sectional Study on Socioeconomic Systems Supporting Outpatients With Parkinson's Disease in Japan. J Epidemiol 2016; 26: 185-190.

216) Kitamura Y, Inden M, Kimoto Y, Takata K, Yanagisawa D, Hijioka M, Ashihara E, Tooyama I, Shimohama S, Ariga H. Effects of a DJ-1-Binding Compound on Spatial Learning and Memory Impairment in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis 2017; 55: 67-72.

217) Iwahara N, Hisahara S, Kawamata J, Matsumura A, Yokokawa K, Saito T, Fujikura M, Manabe T, Suzuki H, Matsushita T, Suzuki S, Shimohama S. Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice. J Alzheimers Dis 2017; 55: 1235-1247.

218) Suzuki A, Shinozaki J, Yazawa S, Ueki Y, Matsukawa N, Shimohama S, Nagamine T. Establishing a New Screening System for Mild Cognitive Impairment and Alzheimer's Disease with Mental Rotation Tasks that Evaluate Visuospatial Function. J Alzheimers Dis 2018; 61: 1653-1665.

219) Takata K, Amamiya T, Mizoguchi H, Kawanishi S, Kuroda E, Kitamura R, Ito A, Saito Y, Tawa M, Nagasawa T, Okamoto H, Sugino Y, Takegami S, Kitade T, Toda Y, Kem WR, Kitamura Y, Shimohama S, Ashihara E. Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease. Neurobiol Aging 2018; 62: 197-209.

220) Miyazaki Y, Niino M, Takahashi E, Suzuki M, Mizuno M, Hisahara S, Fukazawa T, Amino I, Nakano F, Nakamura M, Akimoto S, Minami N, Fujiki N, Doi S, Shimohama S, Terayama Y, Kikuchi S. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis. Clin Immunol 2018; 187: 95-101.

221) Tsuda E, Imai T, Hozuki T, Yamauchi R, Saitoh M, Hisahara S, Yoshikawa H, Motomura M, Shimohama S. Correlation of bite force with excitation-contraction coupling time of the masseter in myasthenia gravis. Clin Neurophysiol 2010; 121: 1051-1058.

222) Hozuki T, Imai T, Tsuda E, Matsumura A, Yamamoto D, Toyoshima T, Suzuki S, Yamauchi R, Hayashi T, Hisahara S, Shimohama S. Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study. Intern Med 2010; 49: 371-376.

223) Imai T, Tsuda E, Toyoshima T, Yoshikawa H, Motomura M, Shimohama S. Anti-ryanodine receptor-positive acetylcholine receptor-negative myasthenia gravis: evidence of impaired excitation-contraction coupling. Muscle Nerve 2011; 43: 294-295.

224) Imai T, Tsuda E, Hozuki T, Yamauchi R, Saitoh M, Hisahara S, Yoshikawa H, Motomura M, Kawamata J, Shimohama S. Early effect of tacrolimus in improving excitation-contraction coupling in myasthenia gravis. Clin Neurophysiol 2012; 123: 1886-1890.

225) Imai T, Tsuda E, Hozuki T, Yoshikawa H, Yamauchi R, Saitoh M, Hisahara S, Motomura M, Kawamata J, Shimohama S. Contribution of anti-ryanodine receptor antibody to impairment of excitation-contraction coupling in myasthenia gravis. Clin Neurophysiol 2012; 123: 1242-1247.

226) Toyoshima T, Yazawa S, Murahara T, Ishiguro M, Shinozaki J, Ichihara-Takeda S, Shiraishi H, Matsuhashi M, Shimohama S, Nagamine T. Load effect on background rhythms during motor execution: A magnetoencephalographic study. Neurosci Res 2016; 112: 26-36.

227) Yamamoto D, Imai T, Tsuda E, Hozuki T, Yamauchi R, Hisahara S, Kawamata J, Shimohama S. Impaired post-

tetanic potentiation of muscle twitch in myasthenia gravis. Clin Neurophysiol 2016; 127: 1689-1693.

228) Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16: 976-986.

229) Yamamoto D, Imai T, Tsuda E, Hozuki T, Yamauchi R, Hisahara S, Kawamata J, Shimohama S. Effect of local cooling on excitation-contraction coupling in myasthenic muscle: Another mechanism of ice-pack test in myasthenia gravis. Clin Neurophysiol 2017; 128: 2309-2317.

別刷請求先：下濱　俊
〒060-8543　札幌市中央区南 1 条西 16 丁目
札幌医科大学医学部神経内科学講座
TEL：011-611-2111（内線 38200）
FAX：011-622-7668
E-mail：shimoha@sapmed.ac.jp